Fiche centre
Indywidualna Praktyka Lekarska prof. Konrad Rejdak
Lublin — Poland
Essais liés3clinical trials
VilleLublinlocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05201638
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ponesimod | SEP | Phase 3 | NCT03232073 | Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | COMPLETED |
| IMU-838 (30 mg/day) | SEP | Phase 2 | NCT03846219 | MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) | ACTIVE_NOT_RECRUITING |
| IMU-838 tablets | SEP | Phase 3 | NCT05201638 | ENSURE-2 — Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |